Dr. Li (left) with lab member looking at slide

Hematology & Oncology Education

The U-M Medical School Department of Internal Medicine Division of Hematology and Oncology is committed and excited to train the future leaders in the field. 

In addition to our Hematology/Oncology Fellowship Training Program, our faculty teach residents in multiple settings, including inpatient services, outpatient clinics, and clinical and laboratory research activities. Moreover, our division has weekly and monthly clinical, research and case conferences, creating an environment of continuous learning and teaching.

Discover education and training opportunities to advance your career.

For More Information

Fellowship Program

Our comprehensive three-year Hematology/Oncology Fellowship Training Program offers dual certification in both hematology and medical oncology. Fellows have the opportunity to complete 18 months of clinical experience, with the remaining time spent in independent research.

Conferences & Lectures

Our division holds regularly scheduled conferences with the majority being available for physicians to earn CME credit. The University of Michigan Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Additional conferences/CME opportunities include:
Hematology Oncology fellows smile

Fellowship Program

Our combined Hematology/Oncology Fellowship Training Program is three years in length and is designed to train the next generation of leaders in academic and clinical hematology, and medical oncology.

Learn more and apply

Explore Your Training Opportunities
Explore Your Training Options at Michigan Medicine

At Michigan Medicine, you’re joining a community where collaboration, curiosity and excellence shape everything we do. Train alongside leaders in medicine and research, grow with mentors who invest in your success, and be part of teams driving meaningful change in health care.

Featured News & Stories

 See all news red blood cells going through clear tube red background
Health Lab

FDA-approved drug offers hope for patients with polycythemia vera, a rare bone marrow disorder

FDA-approved rusfertide offers new hope for polycythemia vera patients by reducing phlebotomy dependence, easing symptoms, and improving daily life.
 little girl with yellow shirt on soccer field smiling ready for soccer
Health Lab

Pediatric patient treated for rare kidney cancer

When 18-month-old Maria was diagnosed with an exceptionally rare kidney cancer, specialists at C.S. Mott Children's Hospital created a customized treatment plan that saved her life.
 Microscope images of prostate cancer cells
Health Lab

New drug combination may help treat advanced prostate cancer

University of Michigan researchers found that combining BET bromodomain and DNMT inhibitors may slow the growth of treatment-resistant prostate cancer by targeting transdifferentiated tumors.